1. Home
  2. WLYB vs NEO Comparison

WLYB vs NEO Comparison

Compare WLYB & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WLYB
  • NEO
  • Stock Information
  • Founded
  • WLYB 1807
  • NEO 2001
  • Country
  • WLYB United States
  • NEO United States
  • Employees
  • WLYB N/A
  • NEO N/A
  • Industry
  • WLYB Books
  • NEO Precision Instruments
  • Sector
  • WLYB Consumer Discretionary
  • NEO Health Care
  • Exchange
  • WLYB Nasdaq
  • NEO Nasdaq
  • Market Cap
  • WLYB 2.4B
  • NEO 2.3B
  • IPO Year
  • WLYB N/A
  • NEO 1999
  • Fundamental
  • Price
  • WLYB $43.70
  • NEO $14.21
  • Analyst Decision
  • WLYB
  • NEO Strong Buy
  • Analyst Count
  • WLYB 0
  • NEO 10
  • Target Price
  • WLYB N/A
  • NEO $20.56
  • AVG Volume (30 Days)
  • WLYB 255.0
  • NEO 1.2M
  • Earning Date
  • WLYB 03-06-2025
  • NEO 02-18-2025
  • Dividend Yield
  • WLYB 3.22%
  • NEO N/A
  • EPS Growth
  • WLYB N/A
  • NEO N/A
  • EPS
  • WLYB N/A
  • NEO N/A
  • Revenue
  • WLYB $1,759,570,000.00
  • NEO $644,118,000.00
  • Revenue This Year
  • WLYB N/A
  • NEO $12.98
  • Revenue Next Year
  • WLYB $1.13
  • NEO $9.94
  • P/E Ratio
  • WLYB N/A
  • NEO N/A
  • Revenue Growth
  • WLYB N/A
  • NEO 12.06
  • 52 Week Low
  • WLYB $32.60
  • NEO $12.13
  • 52 Week High
  • WLYB $52.90
  • NEO $19.11
  • Technical
  • Relative Strength Index (RSI)
  • WLYB 43.40
  • NEO 40.41
  • Support Level
  • WLYB $41.61
  • NEO $13.93
  • Resistance Level
  • WLYB $52.29
  • NEO $16.18
  • Average True Range (ATR)
  • WLYB 0.10
  • NEO 1.12
  • MACD
  • WLYB 0.28
  • NEO -0.37
  • Stochastic Oscillator
  • WLYB 85.31
  • NEO 29.80

About WLYB John Wiley & Sons Inc.

John Wiley & Sons Inc is a provider of academic journals, books, pre- and post-hire assessments and training, test preparation materials, and online education program management solutions. The company's reportable segments are; Research, Learning, Held for Sale or Sold. The majority of the company's revenue is generated from the Research segment which provides peer-reviewed scientific, technical, and medical (STM) publishing, content platforms, and related services to academic, corporate, and government customers, academic societies, and individual researchers. Geographically, it derives maximum revenue from the United States and the rest from the United Kingdom, China, Japan, Canada, and other countries.

About NEO NeoGenomics Inc.

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.

Share on Social Networks: